Valeant Pharmaceuticals International Inc price target slashed, stock downgraded at RBC

Valeant CEO Michael Pearson

Valeant Pharmaceuticals International Inc.’s disclosure that it’s the subject of an SEC probe was enough to convince Douglas Miehm at RBC Capital Markets to finally downgrade the stock .

The analyst also slashed his price target on Valeant share to US$85 from US$194, which still represents upside of roughly 30 per cent.


About admin


Check Also


Twitter Inc’s user growth stalls as sales forecast falls short of estimates

Twitter Inc. said it didn’t add new users in the fourth quarter and forecast first-quarter ...


Manulife Financial Corp profit slides 62% as energy investments take a hit: ‘A disappointing year’

TORONTO – Energy exposure hit the conclusion of Manulife Financial Corp. in the fourth quarter, ...


Pension funds hope for better deal in de-risking marketplace

A pension risk exchange – an online marketplace that aims to create those defined benefit ...